Effects of vitamin D3 supplementation on clinical symptoms, quality of life, serum serotonin (5-hydroxytryptamine), 5-hydroxy-indole acetic acid, and ratio of 5-HIAA/5-HT in patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial

Sikaroudi, Masoumeh Khalighi; Mokhtare, Marjan; Shidfar, Farzad; Janani, Leila; Kashani, Amirhossein Faghihi; Masoodi, Mohsen; Agah, Shahram; Dehnad, Afsaneh; Shidfar, Shahrzad

doi:10.17179/excli2020-2247

Cited by 8 publications

(9 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Author (ref.) Year (Published) Nation Patients (vitamin D/control) Female (%) Follow-up Dose of Vitamin D Supplementation Serum 25(OH)D (vitamin D, baseline) Serum 25(OH)D (control, baseline) Jalili et al [ 7 ] 2016 Iran 25/25 100 6 weeks 50,000 IU/biweek 21.10 ± 8.23 ng/mL 21.23 ± 8.45 ng/mL Abbasnezhad et al [ 8 ] 2016 Iran 44/41 57/85 6 months 50,000 IU/biweek 19.65 ± 10.35 ng/mL 18.62 ± 11.23 ng/mL Amrousy et al [ 9 ] 2018 Egypt 56/56 62/112 6 months 2000 IU/d 17.2 ± 1.3 ng/mL 17.5 ± 1.1 ng/mL Jalili et al [ 10 ] 2019 Iran 58/58 not available 6 weeks 50,000 IU/week 21.10 ± 5.23 ng/mL 21.10 ± 5.23 ng/mL Sikaroudi et al [ 11 ] 2020 Iran 39/35 39/74 9 weeks 50,000 IU/week 18.59 ± 7.58 ng/mL 18.59 ± 7.92 ng/mL Williams et al [ 23 ] 2021 ...…”

Section: Resultsmentioning

confidence: 99%

“…The primary outcome measure was the IBS-SSS and the secondary outcome measure was IBS-QoL score; their effect sizes are represented as mean difference (MD) and standard deviation (SD). However, the data of Jalili et al, 2016 [ 7 ] were represented as MD and standard error, those of Sikaroudi et al, 2020 [ 11 ] as median and first and third quartiles, and those of Jalili et al, 2019 [ 10 ] as only baseline and change MD and standard error. All data were converted to MD and SD according to the Cochrane Handbook [ 19 ] and the McGrath et al study [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

“…Interestingly, many studies have consistently reported the presence of a vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) < 50 nmol/L or 20 ng/mL) in IBS patients [ 5 , 6 ]. Moreover, some randomized controlled trials (RCT) reported that taking vitamin D supplements improve IBS symptoms [ [7] , [8] , [9] , [10] , [11] ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vitamin D improves irritable bowel syndrome symptoms: A meta-analysis

Yan

Chen

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D improves irritable bowel syndrome symptoms: A meta-analysis

Yan

Chen

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…In a study conducted on Iranian patients diagnosed with irritable bowel syndrome and with baseline calcidiol concentrations below 30 ng/mL (75 nmol/L), supplementation with 50,000 IU (1250 μg) of vitamin D 3 once weekly for nine weeks increased calcidiol concentration significantly (18.59 ± 7.58 vs. 46.86 ± 12 ng/mL, p < 0.001). In addition, after supplementation, the intervention group presented an improvement in the Hospital Anxiety and Depression Scale based on the decrease in the mean score (6.59 ± 4.63 vs. 5.26 ± 4.68, p = 0.008); however, the final score did not differ from the placebo group (5.26 ± 4.68 vs. 6.06 ± 3.8, p = 0.425) [ 22 ].…”

Section: Vitamin D Supplementation For the Treatment Of Depressionmentioning

confidence: 99%

“…This could be explained because vitamin D deficiency can alter the availability of some cholinergic, dopaminergic, and noradrenergic neurotransmitters, which have been implicated in depression [ 21 ]. In addition, some studies have shown that vitamin D supplementation may improve the clinical depressive state [ 22 , 23 ]. Vitamin D also can modulate proinflammatory cytokines (e.g., IL-6 and TNF-α), which are essential in systemic inflammation associated with depression and suicide [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Vitamin D in Depression: A Potential Bioactive Agent to Reduce Suicide and Suicide Attempt Risk

Somoza-Moncada

Turrubiates-Hernández

Muñoz‐Valle

et al. 2023

Nutrients

View full text Add to dashboard Cite

Suicide is one of the leading causes of death worldwide. According to the World Health Organization (WHO), every year, more than 700 thousand people die from this cause. Therefore, suicide is a public health issue. The complex interaction between different factors causes suicide; however, depression is one of the most frequent factors in people who have attempted suicide. Several studies have reported that vitamin D deficiency may be a relevant risk factor for depression, and vitamin D supplementation has shown promising effects in the adjunctive treatment of this mood disorder. Among the beneficial mechanisms of vitamin D, it has been proposed that it may enhance serotonin synthesis and modulate proinflammatory cytokines since low serotonin levels and systemic inflammation have been associated with depression and suicide. The present narrative review shows the potential pathogenic role of vitamin D deficiency in depression and suicide and the potential benefits of vitamin D supplementation to reduce their risk.

show abstract

Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial

Williams

Corfe

2021

Eur J Nutr

View full text Add to dashboard Cite

Purpose Several small trials suggest a benefit of vitamin D supplementation in irritable bowel syndrome (IBS). The generalisability of these reports is limited by their design and scale. This study aimed to assess whether vitamin D supplementation improved IBS symptoms in a UK community setting. Methods This was a randomised, double-blind, placebo-controlled study. Participants were recruited from the community in winter months between December 2017 and March 2019. 135 participants received either vitamin D (3,000 IU p.d.) or placebo for 12 weeks. The primary outcome measure was change in IBS symptom severity; secondary outcomes included change in IBS-related quality of life. Results The participants were analysed on an intent-to-treat basis. 60% of participants were vitamin D deficient or insufficient at baseline. Although vitamin D levels increased in the intervention arm relative to placebo (45.1 ± 32.88 nmol/L vs 3.1 ± 26.15 nmol/L; p < 0.001). There was no difference in the change of IBS symptom severity between the active and placebo trial arms (− 62.5 ± 91.57 vs – 75.2 ± 84.35, p = 0.426) over time. Similarly there was no difference between trial arms in τhe change in quality of life (− 7.7 ± 25.36 vs – 11.31 ± 25.02, p = 0.427). Conclusions There is no case for advocating use of vitamin D in the management of IBS symptoms. The prevalence of vitamin D insufficiency suggests routine screening and supplementation should be implemented in this population for general health reasons. This trial was retrospectively registered with ISRCTN (ISRCTN13277340) on 24th April 2018 after recruiting had been initiated.

show abstract

Effects of vitamin D3 supplementation on clinical symptoms, quality of life, serum serotonin (5-hydroxytryptamine), 5-hydroxy-indole acetic acid, and ratio of 5-HIAA/5-HT in patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial

Cited by 8 publications

References 67 publications

Vitamin D improves irritable bowel syndrome symptoms: A meta-analysis

Vitamin D improves irritable bowel syndrome symptoms: A meta-analysis

Vitamin D in Depression: A Potential Bioactive Agent to Reduce Suicide and Suicide Attempt Risk

Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial

Contact Info

Product

Resources

About